#1 - AbbVie (NYSE:ABBV)
AbbVie Inc. (NYSE: ABBV) is frequently talked about as one of the best income stocks. That’s backed up by the company’s status as a dividend king. But there are several reasons to believe that growth-oriented investors will want to take a closer look at this biopharmaceutical sector leader.
The company’s revenue and earnings were expected to take a hit after it lost patent expiration on its blockbuster drug, Humira, in 2023. However, AbbVie has launched drugs like Skyrizi and Rinvoq, which have helped mitigate the impact of lower Humira sales.
And although AbbVie already has a deep pipeline of drug candidates, that didn’t stop it from acquiring Nimble Therapeutics in December 2024 to add even more potential autoimmune drugs that it can bring to market.
Analysts project AbbVie to grow earnings at around 20%. If that’s accurate, ABBV stock is more likely to deliver a total return closer to its five-year average of around 28%.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $169.19
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $205.50 (21.5% Upside)
